Date: 2017-02-28
Type of information: Capital increase
Company: Paion (Germany)
Investors:
Amount: € 4.99 million
Funding type: capital increase
Planned used:
- Paion intends to use the proceeds of the capital increase primarily to prepare and submit an application for approval of remimazolam in Japan.
Others:
- • On February 28, 2017, Paion announced that the company has successfully completed its rights offering. A total of 2,439,023 new shares were subscribed for and issued under this transaction. The U.S. institutional investor that has supported the rights offering by way of commitment to subscribe for all shares that were not subscribed for by existing shareholders or excluded, has subscribed for 89,922 new shares. With the completion of this transaction, the Company’s share capital has been increased from € 55,757,094.00 by € 2,439,023.00 to € 58,196,117.00 by issuing 2,439,023 new shares. The offering utilized parts of the existing authorized capital as created by resolution by the Annual General Meeting on 20 May 2015. Paion has received gross proceeds totalling € 4.99 million under the rights offering. The transaction was accompanied by Oddo Seydler Bank .
- • On February 7, 2017, Paion announced that its management board has decided with the approval of the Supervisory Board of the same day, to increase the company's registered share capital against contribution in cash from € 55,757,094.00 by € 2,439,023.00 to € 58,196,117.00 by issuing 2,439,023 new, registered, no-par value shares with a notional value of € 1.00, each with full dividend entitlement as of the fiscal year beginning 01 January 2016 while granting subscription rights to existing shareholders. The subscription price is € 2.05 per share.
Therapeutic area: CNS diseases
Is general: Yes
